Reports Q2 revenue $16.04M, consensus $15.41M. The company reported net FUROSCIX revenue of $16M, up 99% vs. last year. Cash and cash equivalents were $40.8M as of June 30, 2025. scPharmaceuticals (SCPH) adds that its autoinjector remains on track for a supplemental New Drug Application submission in Q3. “We’re very pleased with the continued momentum behind FUROSCIX, with net revenue of $16 million in the second quarter. We believe this growth reflects strong execution across our organization and increasing adoption by prescribers who recognize the clinical and economic value that FUROSCIX brings to patient care,” said CEO John Tucker.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SCPH: